Last updated : May 13, 2026 1:40 pm
We are building an AI-native operating system for pharma sales and distribution
In an exclusive interaction with Rahul Koul, Editor, Indian Pharma Post, Dushyant Sapre explains why India’s pharma distribution challenges inspired SwishX to build Agentic AI solutions and SwishX’s vision to serve 10,000 pharma companies globally. Read the detailed interview.
SwishX describes itself as the world’s first AI-native operating system for pharma sales and distribution. What makes it different from other AI companies in healthcare?
Most AI investments globally, especially in the US and Europe, are focused on drug discovery and accelerating R&D for innovative therapies. But emerging markets like India are driven largely by generic drugs, where the real challenge is not discovery but commercial execution such as sales, tenders, hospital contracts, marketing, and distribution. Historically, enterprise software in pharma has been built as a “system of record.” It captures data such as sales numbers, doctor visits, or inventory movement, but it doesn’t take action.
SwishX was built post-2023 in the era of AI agents. We are not just recording business activity; our AI agents actively interpret data, automate workflows, and generate operational intelligence in real time. That’s why we call ourselves AI-native. We are building AI-first commercial infrastructure for pharma and medtech companies rather than retrofitting AI into legacy systems.
Why did SwishX choose to focus on pharma commercial operations instead of drug discovery?
India is the pharmacy of the world. It supplies medicines to more than 200 countries and dominates generic drug manufacturing. In the generic drug business, differentiation comes from commercial execution rather than product exclusivity. If a company develops a patented innovative drug, it already has a 20-year market advantage. But generic manufacturers compete on distribution efficiency, tender participation, hospital contracts, and market reach. That is where AI can create immediate business impact.
We felt that emerging markets needed AI solutions built around commercial intelligence rather than molecule discovery. That insight shaped SwishX.
Pharma companies often struggle with fragmented data spread across multiple systems. How does SwishX solve that challenge?
Most pharma companies today operate through disconnected software ecosystems such as CRM platforms, ERP systems, marketing tools, doctor engagement platforms, tender systems, and supply-chain applications. Replacing all of them is unrealistic. What we do instead is deploy AI agents that act like virtual employees. These agents log into existing systems, collect data, connect the context across platforms, and generate actionable insights. For example, an AI agent can correlate doctor engagement activities with prescription growth or tie field sales activity to revenue performance in a specific geography. Earlier, pharma companies had no way to connect those dots effectively. The beauty is that companies don’t need to replace their SAP, Salesforce, or Microsoft systems. We sit on top of existing infrastructure and extract intelligence from it.
Can you explain the core products within the SwishX platform?
We have structured SwishX into four specialized hubs. First is Tender IQ that automates tender and RFP management for pharma and medtech firms. It can analyze hundreds of pages of tender documents, identify relevant opportunities, recommend pricing, and generate bid documents. Second is Contract IQ that focuses on hospital rate contracts and helps reduce revenue leakage, which is a major problem in pharma distribution.
Third is Marketing IQ that onverts long pharma marketing PDFs into compliant, doctor-friendly video reels within minutes. Fourth is Channel IQ that helps pharma companies engage retailers and distributors while improving visibility into secondary sales. Each hub is powered by dedicated AI agents trained specifically for pharma commercial workflows.
Hospital rate contracts are a major issue for pharma companies. How does Contract IQ address revenue leakage?
Revenue leakage in hospital contracts is an industry-wide challenge. Hospitals receive medicines at special negotiated prices, but in many cases excess quantities leak into the open market. Our AI models analyze procurement patterns, hospital bed capacity, ordering frequency, and other operational indicators to flag suspicious transactions. Companies using Contract IQ have been able to reduce leakage levels significantly within a few months. That directly impacts profitability.
How is AI transforming pharma marketing through Marketing IQ?
Pharma companies still rely heavily on PDFs and static promotional content. Doctors simply don’t have time to read lengthy documents anymore. Marketing IQ converts those documents into compliant short-form video reels optimized for doctor engagement. What earlier took agencies two to three weeks can now happen within minutes. More importantly, because the content is digital, companies can measure engagement rates and correlate them with prescription trends. For the first time, marketing teams can clearly see what is actually working.
Are traditional pharma companies ready to adopt AI-driven systems?
Adoption is happening faster than many people expected because pharma companies are under pressure to improve efficiency and revenue outcomes. The key is measurable impact. We deliberately focused on areas where results are directly visible in terms of increased tender participation, reduced leakage, higher secondary sales, or better marketing engagement.
Interestingly, the resistance today is not necessarily from promoters or CEOs. Many leadership teams are actually eager to adopt AI. The hesitation sometimes comes from middle layers worried about change management or whether teams are prepared for AI-driven workflows.
We have also seen that next-generation family members entering pharma businesses are becoming strong champions of digital transformation.
There are concerns globally around AI ethics, privacy, and data security. How is SwishX addressing those issues?
Data safety and credibility are non-negotiable for us. From day one, we designed the platform with enterprise-grade security. All customer data is encrypted both at rest and in transit. Even internal employees, including me, cannot access customer data unless they have authorized credentials.
For large pharma clients, we also offer deployment on the customer’s own servers. That gives companies additional control and comfort around data governance. If you want to build a global AI company in healthcare, ethics and trust have to be foundational.
SwishX plans to expand into Latin America, Southeast Asia, Africa, and the Middle East. Why are emerging markets central to your strategy?
Emerging markets share similar commercial challenges such as fragmented distribution, large retail networks, complex tenders, and growing private healthcare systems. India alone has nearly 1.2 million pharmacy outlets, far more than many developed markets. Countries like Brazil and Indonesia face similar scale complexities.
We believe emerging markets require their own AI stack designed specifically for these realities. That is our unfair advantage because we understand these ecosystems deeply.
What is your long-term vision for SwishX?
Our vision is not just about revenue. We want to build products valuable enough to serve 10,000 pharmaceutical and medtech companies across emerging markets. Today we are focused on commercial operations, but over time we want to support the entire pharma lifecycle, from generic drug development and compliance to distribution, marketing, and market expansion. Ultimately, we want SwishX to become the most customer-obsessed AI company in life sciences.
How do you see AI reshaping pharma commercial operations over the next decade?
I believe 70–80% of the commercial processes that exist today will disappear within the next decade. The stakeholders be it pharma companies, distributors, hospitals, retailers, and doctors, all will remain the same, but the way they interact will change dramatically. AI agents will automate repetitive operational tasks, accelerate decision-making, improve access to medicines, and reduce friction across the ecosystem.
Commercial operations in pharma will become always-on, real-time, and intelligence-driven. That transformation has already started.